Mark D. Perrin is the CEO and a director of InVivo Therapeutics Corporation. Mr. Perrin most recently served as President of Dennan Consulting, a biotech consulting firm. From 2005 to 2010, he served as President and Chief Executive Officer of ConjuChem Biotechnologies. From 2002 to 2005, he was Executive Vice President and Chief Commercial Officer for Orphan Medical, until the company was acquired by Jazz Pharmaceuticals. From 1995 to 2001, he was Executive Vice President, Commercial Operations for COR Therapeutics. Earlier in his career, he was Vice President for Burroughs Wellcome and for Lederle Laboratories, with responsibility for all U.S. commercial operations at each company.
Interview with the CEO: InVivo Therapeutics Corporation (NVIV)
July 24, 2014